# US 2026/0083361 A1 · Non-invasive determination of a physiological state of interest in a subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083361 A1
- Document ID: US20260083361A1
- Status: Published application
- Kind: A1
- Application number: 18/430,330
- Filed: 2024-02-01
- Published: 2026-03-26
- Earliest claimed: 2018-05-15
- Assignees: Isbrg Corp.
- Applicants: Isbrg Corp.
- Inventors: Duncan James MacIntyre
- Web page: https://patentgrep.com/patent/US20260083361A1

## CPC

- A61B 5/0075: {by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy (A61B5/0071 takes precedence)}
- A61B 5/1455: using optical sensors, e.g. spectral photometrical oximeters
- A61B 5/1451: {for interstitial fluid}
- A61B 5/14551: {for measuring blood gases}
- A61B 5/4845: {Toxicology, e.g. by detection of alcohol, drug or toxic products (A61B5/4848 takes precedence)}
- A61B 5/6826: {Finger}
- A61B 5/7264: {Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems}
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- A61B 5/14546: {for measuring analytes not otherwise provided for, e.g. ions, cytochromes}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

A method for non-invasively determining a physiological state of interest in a subject is described. The method involves, placing a body part in contact with a receptor, and directing a source of electromagnetic radiation (EMR) over a range of wavelengths onto body part so that the EMR reaches the blood and interstitial fluid within the body part. The EMR that is absorbed by, reflected by, or transmitted through, the blood and interstitial fluid of the body part is measured, and a spectrum over the range of wavelengths obtained. The spectrum is analyzed to determine an amount of two or more than two analytes within the blood and interstitial fluid of the body part and a biochemical profile is derived. The biochemical profile is used to determine the physiological state of interest in the subject. The physiological state of interest in the subject may be selected from the group of intoxication arising from cannabis, alcohol, a combination of cannabis and alcohol, opiates, fentanyl, amphetamines, phencyclidine, sedatives, anxyolytics, cocaine, caffeine, and nicotine consumption.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method of non-invasively determining a physiological state of interest of a subject, the method comprising:
placing a body part in contact with a receptor;
directing a source of electromagnetic radiation (EMR) over a range of wavelengths through the receptor and onto the body part so that the EMR reaches the blood and interstitial fluid within the body part;
measuring the EMR absorbed by, reflected by, or transmitted through, the blood and interstitial fluid of the body part with a detector to obtain a spectrum over the range of wavelengths;
performing a quantitative mathematical analysis of the spectrum to determine an amount of at least one known analyte within the blood and interstitial fluid of the body part;
deriving a biochemical profile amount of the at least one known analyte and from the spectrum corresponding to multiple ghost analytes whose identities are unknown and that are observed to change in response to the physiological state of interest; and
analyzing the biochemical profile to determine the physiological state of interest of the subject.

### Claim 15 (depends on 14)

The method of claim 14, wherein in the range of wavelengths is from about 400 nm to about 2,500 nm.

### Claim 16 (depends on 15)

The method of claim 15, wherein the physiological state of interest of the subject is selected from the group consisting of: intoxication arising from cannabis, alcohol, a combination of cannabis and alcohol, opiates, fentanyl, amphetamines, phencyclidine, sedatives, anxyolytics, cocaine, caffeine, and nicotine consumption.

### Claim 17 (depends on 16)

The method of claim 16, wherein the physiological state of interest is:
i) cannabis-induced intoxication, and the at least one known analyte is selected from the group consisting of: delta-9-tetrahydrocannabinol (THC), THC glucuronide (THCGlu), 11-nor-9-carboxy-THC (THC-COOH), 11-hydroxy THC (11-OH-THC), THC-COOH/11-OH-THC ratio, 11-nor-9-carboxy-THC glucuronide (THC-COOGlu), cannabidol (CBD), cannbinol (CBN), cannabigerol (CBG), delta-9-tetrahydrocannabivarin (THCV), THCV-carboxylic acid, 11-nor-9-carboxy-delta-tetrahydrocannabivarin (THCV-COOH), total protein, bilirubin, prolactin, triglycerides, creatinine, cortisol, glucose, lactate, Total 4, uric acid, blood urea nitrogen (BUN), blood sugar, calcium, ionized calcium, magnesium, sodium, phosphate, and GABA;
ii) alcohol-induced intoxication, and the at least one known analyte is selected from the group consisting of: alcohol, aldehyde, lactic acid; or
iii) intoxication arising from cannabis, alcohol, opiates, fentanyl, amphetamines, phencyclidine, sedatives, anxyolytics, cocaine, caffeine, and nicotine consumption, and the at least one known analyte is selected from the group consisting of: delta-9-tetrahydrocannabinol (THC), THC glucuronide (THCGlu), 11-nor-9-carboxy-THC (THC-COOH), 11-hydroxy THC (11-OH-THC), THC-COOH/11-OH-THC ratio, 11-nor-9-carboxy-THC glucuronide (THC-COOGlu), cannabidol (CBD), cannbinol (CBN), cannabigerol (CBG), delta-9-tetrahydrocannabivarin (THCV), THCV-carboxylic acid, 11-nor-9-carboxy-delta-tetrahydrocannabivarin (THCV-COOH), albumin, apolipoproteins A1 and B (apoA1 and apoB), total protein, bilirubin, prolactin, triglycerides, creatinine, cortisol, glucose, lactate, Total 4, uric acid, blood urea nitrogen (BUN), blood sugar, calcium, ionized calcium, magnesium, sodium, phosphate, GABA, alcohol, aldehyde, and lactic acid.

### Claim 18 (depends on 14)

The method of claim 14, wherein the physiological state of interest of the subject is determined by:
processing a plurality of data sets that are representative of the biochemical profile and that have been obtained from a plurality of subjects;
cross validating the plurality of data sets; and
training at least one deep neural network, support vector machine, convolutional neural network, or generalized additive model to develop a model to identify sets of analytes associated with the status of the physiological state of interest, wherein the model is used to analyze the biochemical profile of the subject to determine the physiological state of interest of the subject.

### Claim 19 (depends on 18)

The method of claim 18, wherein the model is iteratively trained and validated using different data sets to produce a validated model, the validated model used to identify the sets of analytes associated with the status of the physiological state of interest.

### Claim 20 (depends on 14)

The method of claim 14, further comprising:
determining at least one physiological parameter of the subject; and
analyzing the at least one physiological parameter in addition to the biochemical profile to determine the physiological state of interest of the subject.

### Claim 21 (depends on 14)

The method of claim 14, wherein the biochemical profile changes over time.

### Claim 22 (depends on 14)

The method of claim 14, wherein the biochemical profile is a ratio of relative amounts of the at least one known analyte and the ghost analytes.

### Claim 23 (depends on 14)

The method of claim 14, wherein the biochemical profile is an index of biologically active to biologically inactive analytes.

### Claim 24

A device for detecting a physiological state of interest of a subject, comprising:
a source of electromagnetic radiation (EMR) that emits a plurality of wavelengths of EMR, the source of EMR being operatively coupled to a power source;
a receptor sized to receive a body part, the receptor comprising at least one port;
a detector for measuring transmitted or reflected EMR received from the body part;
at least one input radiation guiding element in operable association with the source of EMR, and at least one output radiation guiding element in operable association with the detector, wherein the at least one input radiation guiding element and the at least one output radiation guiding element are in optical alignment with the at least one port thereby defining an EMR path within the receptor when the receptor is receiving the body part;
a processing system operatively coupled to the detector and configured to:
direct the source of electromagnetic radiation (EMR) over the plurality of wavelengths through the receptor and onto the body part so that the EMR reaches blood and interstitial fluid within the body part;
measure the EMR absorbed by, reflected by, or transmitted through, the blood and interstitial fluid of the body part with the detector to obtain a spectrum over the plurality of wavelengths;
perform a quantitative mathematical analysis of the spectrum to determine an amount of at least one known analyte within the blood and interstitial fluid of the body part;
derive a biochemical profile amount of the at least one known analyte and from the spectrum corresponding to multiple ghost analytes whose identities are unknown and that are observed to change in response to the physiological state of interest; and
analyze the biochemical profile to determine the physiological state of interest of the subject.

### Claim 25 (depends on 25)

The device of claim 25, wherein in the plurality of wavelengths span from about 400 nm to about 2,500 nm.

### Claim 26 (depends on 25)

The device of claim 25, wherein the physiological state of interest of the subject is selected from the group consisting of: intoxication arising from cannabis, alcohol, a combination of cannabis and alcohol, opiates, fentanyl, amphetamines, phencyclidine, sedatives, anxyolytics, cocaine, caffeine, and nicotine consumption.

### Claim 27 (depends on 26)

The device of claim 26, wherein the physiological state of interest is:
i) cannabis-induced intoxication, and the at least one known analyte is selected from the group consisting of: delta-9-tetrahydrocannabinol (THC), THC glucuronide (THCGlu), 11-nor-9-carboxy-THC (THC-COOH), 11-hydroxy THC (11-OH-THC), THC-COOH/11-OH-THC ratio, 11-nor-9-carboxy-THC glucuronide (THC-COOGlu), cannabidol (CBD), cannbinol (CBN), cannabigerol (CBG), delta-9-tetrahydrocannabivarin (THCV), THCV-carboxylic acid, 11-nor-9-carboxy-delta-tetrahydrocannabivarin (THCV-COOH), total protein, bilirubin, prolactin, triglycerides, creatinine, cortisol, glucose, lactate, Total 4, uric acid, blood urea nitrogen (BUN), blood sugar, calcium, ionized calcium, magnesium, sodium, phosphate, and GABA;
ii) alcohol-induced intoxication, and the at least one known analyte is selected from the group consisting of: alcohol, aldehyde, lactic acid; or
iii) intoxication arising from cannabis, alcohol, opiates, fentanyl, amphetamines, phencyclidine, sedatives, anxyolytics, cocaine, caffeine, and nicotine consumption, and the at least one known analyte is selected from the group consisting of: delta-9-tetrahydrocannabinol (THC), THC glucuronide (THCGlu), 11-nor-9-carboxy-THC (THC-COOH), 11-hydroxy THC (11-OH-THC), THC-COOH/11-OH-THC ratio, 11-nor-9-carboxy-THC glucuronide (THC-COOGlu), cannabidol (CBD), cannbinol (CBN), cannabigerol (CBG), delta-9-tetrahydrocannabivarin (THCV), THCV-carboxylic acid, 11-nor-9-carboxy-delta-tetrahydrocannabivarin (THCV-COOH), albumin, apolipoproteins A1 and B (apoA1 and apoB), total protein, bilirubin, prolactin, triglycerides, creatinine, cortisol, glucose, lactate, Total 4, uric acid, blood urea nitrogen (BUN), blood sugar, calcium, ionized calcium, magnesium, sodium, phosphate, GABA, alcohol, aldehyde, and lactic acid.

### Claim 28 (depends on 24)

The device of claim 24, wherein processing system is further configured to determine the physiological state of interest of the subject by:
processing a plurality of data sets that are representative of the biochemical profile and that have been obtained from a plurality of subjects;
cross validating the plurality of data sets; and
training at least one deep neural network, support vector machine, convolutional neural network, or generalized additive model to develop a model to identify sets of analytes associated with the status of the physiological state of interest, wherein the model is used to analyze the biochemical profile of the subject to determine the physiological state of interest of the subject.

### Claim 29 (depends on 27)

The device of claim 27, wherein the model is iteratively trained and validated using different data sets to produce a validated model, the validated model used to identify the sets of analytes associated with the status of the physiological state of interest.

### Claim 30 (depends on 24)

The device of claim 24, wherein the processing system is further configured to:
determine at least one physiological parameter of the subject; and
analyze the at least one physiological parameter in addition to the biochemical profile to determine the physiological state of interest of the subject.

### Claim 31 (depends on 24)

The device of claim 24, wherein the biochemical profile changes over time.

### Claim 32 (depends on 24)

The device of claim 24, wherein the biochemical profile is a ratio of relative amounts of the at least one known analyte and the ghost analytes.

### Claim 33 (depends on 24)

The device of claim 24, wherein the biochemical profile is an index of biologically active to biologically inactive analytes.
